Investment Rating - The report maintains an "Outperform" rating for the company, with a target price of 39.6 yuan based on a 30x PE for 2026 [4][9]. Core Insights - The company is building a health business platform through both organic growth and acquisitions, focusing on "oral care + probiotics" [4][11]. - The probiotics segment is expected to significantly contribute to revenue growth, with projected EPS of 0.99, 1.32, and 1.73 yuan for 2025-2027, indicating a strong recovery and growth trajectory [4][9]. - The probiotics market in China has grown from 648 billion yuan in 2018 to 1189 billion yuan in 2023, with a CAGR of approximately 12.4%, and is expected to exceed 1400 billion yuan by 2025 [4][9]. Financial Summary - Total revenue is projected to grow from 1,067 million yuan in 2023 to 1,966 million yuan in 2027, reflecting a compound annual growth rate (CAGR) of approximately 13.7% [3]. - Net profit (attributable to the parent company) is expected to recover from a loss of 77 million yuan in 2024 to a profit of 174 million yuan by 2027 [3]. - The company’s gross margin is projected to improve from 23.2% in 2023 to 27.7% in 2027, indicating enhanced profitability [3]. Business Development - The company has transitioned from a toothbrush OEM to a diversified platform, expanding its product range to include toothpaste and other oral care items, while also entering the probiotics market through the acquisition of a controlling stake in a probiotics company [11][30]. - The probiotics business, particularly the AKK strain, is expected to drive significant growth, with the segment achieving a revenue of 497.6 million yuan in the first half of 2025, marking an 82% year-on-year increase [4][39]. Market Position - The company is a leading manufacturer in the oral care and disposable hygiene products sector in China, with a strong focus on ODM (Original Design Manufacturer) for toothbrushes and wet wipes [4][11]. - The company’s product categories include toothbrushes, toothpaste, dental floss, and wet wipes, with a significant portion of revenue coming from the probiotics segment, which is rapidly growing [4][18].

Company Overview - The company introduced its development history, main business segments, and products during the investor relations activity [1]. Financial Performance - The main product line, the vitamin and mineral series, has shown steady growth through product category expansion and channel development [2]. - The overall gross margin has fluctuated due to product structure and channel influences, with vitamin and mineral products being the highest revenue contributors [3][4]. - The growth rate of vitamin and mineral health foods has outpaced that of functional foods, leading to a decline in overall gross margin [4]. Business Development - The acquisition of Zhongke Jiayi has positively impacted the probiotics business, leveraging brand synergy and establishing partnerships with major clients in the health food sector [2]. - The "Armor Probiotics Intelligent Manufacturing Upgrade Project" was launched at the end of September 2025, aimed at enhancing product, cost, efficiency, and market aspects [2]. Market Opportunities - The market potential for smoking cessation products, particularly Varenicline, is significant due to the large number of smokers in China, with sales expected to grow as awareness increases [2]. - The company collaborates with authoritative smoking cessation organizations to promote public health education and research [2]. Product Development - New products like Minsheng Lesuke and Minsheng Xunfa are in the early stages of market entry, with no sales data available yet [4]. - The company anticipates that initial consumer education for new products will require investment but will not significantly impact overall sales expense ratios or profit levels [4]. Future Plans - The company plans to continue expanding its sample store network in various cities, focusing on optimizing operational models and enhancing customer experience [2].

Investment Rating - The investment rating for the company is "Buy" (maintained) [8] Core Views - The company's probiotic business shows steady growth, with a remarkable revenue performance in Q1 2025 [8] - The company reported a slight decline in 2024 performance but anticipates accelerated revenue growth in 2025 due to strategic transformations and new customer acquisitions [8] Financial Summary - Total revenue for 2024 is projected at 303 million, with a year-on-year growth of 1.19% [8] - Net profit attributable to shareholders for 2024 is expected to be 94.36 million, reflecting a year-on-year increase of 0.94% [8] - The company forecasts a significant revenue increase in 2025, with total revenue expected to reach 434.57 million, representing a year-on-year growth of 43.52% [8] - The earnings per share (EPS) for 2024 is estimated at 0.36 yuan, with projections of 0.47 yuan for 2025 [8] - The price-to-earnings (P/E) ratio is expected to decrease from 40.27 in 2024 to 30.55 in 2025 [8] Business Performance - The probiotic business is expected to maintain a strong growth momentum, with a projected revenue increase of 26% in Q1 2025 [8] - The animal and plant micro-ecological preparation business is anticipated to see a significant growth of over 200% year-on-year in Q1 2025 due to new factory production [8] - The company is optimizing its product structure, which has positively impacted its gross margin, although the animal and plant business has slightly dragged down profitability in Q1 2025 [8]